Clinical trials: Recurrent Glioblastoma Multiforme
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Cancer
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A).
- Trial name
- NCT01812616
- Testing
- Sativex
- Where
- 11 sites in Germany, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Recurrent Glioblastoma Multiforme
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
This is a single arm clinical study to estimate the safety, tolerability and pharmacokinetic (PK) characteristics of Chimeric Antigen Receptor-modified T cells (CAR-T) SNC-109 in patients with recurrent glioblastoma (r-GBM) and…
- Trial name
- NCT05868083
- Testing
- SNC-109 CAR-T Cells
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Recurrent Glioblastoma
Phase 2 Clinical Trial of KH617
To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma
- Trial name
- NCT07138001
- Testing
- KH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16
- Volunteers
- 60 people
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
Glioblastoma
Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma
This is an open-label, single arm, Phase 1 study to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide in adult patients with recurrent glioblastoma or gliosarcoma.
- Trial name
- NCT01499251
- Testing
- Phase 1 Dose Escalation, Phase 1b, Ancillary Study
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Actelion
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Glioblastoma
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human interleukin-12 (IL-12).
- Trial name
- NCT03636477
- Testing
- Ad-RTS-hIL-12, veledimex, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Alaunos Therapeutics
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Recurrent GBM
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk.
- Trial name
- CDX-110 (NCT03068650)
- Testing
- rindopepimut
- Sponsor
- Celldex Therapeutics
Glioma
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
This study is being conducted to characterize the safety/tolerability of pazopanib and lapatinib when administered in combination with enzyme-inducing anticonvulsants in patients with recurrent Grade III or IV malignant gliomas.
- Trial name
- VEG102857 (NCT00350727)
- Testing
- pazopanib, lapatinib
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Recurrent Glioblastoma Multiforme
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC…
- Trial name
- NCT01756729
- Testing
- NovoTTF-100A
- Where
- 12 sites in United States
- Volunteers
- 13 people
- Sponsor
- NovoCure Ltd.
Recurrent Glioblastoma
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.
- Trial name
- NCT03856099
- Testing
- TTAC-0001
- Where
- 3 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- PharmAbcine
Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
- Trial name
- NCT00062504
- Testing
- Talampanel
- Volunteers
- 30 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Glioblastoma Multiforme, GBM
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred…
- Conditions
- Glioblastoma Multiforme, GBM, Gliosarcoma
- Trial name
- NCT01124539
- Testing
- AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
- Where
- 9 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Arno Therapeutics
Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00562419
- Testing
- CT-322, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
Glioblastoma Multiforme
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with…
- Trial name
- NCT04277221
- Testing
- Autologous Dendritic Cell/Tumor Antigen, ADCTA
- Where
- 7 sites in Taiwan
- Volunteers
- 118 people
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Recurrent Glioblastoma Multiforme
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
This is a multicenter, open-label, Phase 1b/2 efficacy and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy (or futility) of a single arm of Berubicin treatment, administered at the recommended…
- Trial name
- NCT04915404
- Testing
- Berubicin Hydrochloride
- Where
- 2 sites in Poland
- Volunteers
- 5 people
- Sponsor
- WPD Pharmaceuticals Sp. z o.o.